News & Updates

Ocular complications develop in RA, connective tissue disease, vasculitis patients

20 Jul 2024

Nearly one-fifth of patients with rheumatoid arthritis (RA) develop ocular complications, as do one-quarter to one-third of those with connective tissue diseases and vasculitis, according to a recent study.

Ocular complications develop in RA, connective tissue disease, vasculitis patients

20 Jul 2024

Novel agent plus ritonavir show favourable signals for mild-to-moderate COVID-19

10 Jul 2024 by

A combination regimen comprising the novel agent GST-HG171 (also known as atilotrelvir) and ritonavir improves clinical symptom recovery and viral clearance in low-risk vaccinated adults with mild-to-moderate COVID-19, findings from a pivotal phase II/III study have shown.

Novel agent plus ritonavir show favourable signals for mild-to-moderate COVID-19

10 Jul 2024

ITSH article 2.1

08 Jul 2024 by

Bleeding disorders, such as Von Willebrand disease (VWD), platelet function disorder (PFD), thrombocytopenia, and clotting factor deficiencies, are more prevalent among adolescent girls with heavy menstrual bleeding (HMB), according to a study presented at RCOG World Congress 2018.

ITSH article 2.1

08 Jul 2024

ITSH article 2.2

08 Jul 2024 by

Extended clopidogrel monotherapy after a 9- to 12-month course of dual antiplatelet therapy (DAPT) reduces bleeding and ischaemic events in patients with acute coronary syndrome (ACS) who are at high risk for both events, according to the OPT-BIRISK* trial presented at ESC 2023.

ITSH article 2.2

08 Jul 2024

ACOG article 2.6

05 Jul 2024 by

Treatment with fezolinetant significantly reduced the frequency and severity of vasomotor symptoms (VMS), particularly hot flashes, in women during their menopausal phase, according to the SKYLIGHT 1* trial presented at ACOG 2022.

Higher levels of social engagement during midlife are associated with a reduced risk of dementia later in life, according to a study presented at AAIC 2023.

Scenario 3

03 Jul 2024

Neoadjuvant cycles do not alter perioperative nivolumab benefit in resectable NSCLC

02 Jul 2024 by

Treatment with nivolumab plus chemotherapy before surgery followed by nivolumab after surgery yields superior outcomes for patients with resectable nonsmall cell lung cancer (NSCLC) as compared with placebo plus chemotherapy, regardless of the number of completed neoadjuvant cycles, according to an exploratory analysis of the CHECKMATE 77T trial.

Neoadjuvant cycles do not alter perioperative nivolumab benefit in resectable NSCLC

02 Jul 2024

Once-monthly subcutaneous amivantamab fares well in advanced solid tumours

02 Jul 2024 by

In individuals with advanced solid malignancies, subcutaneous (SC) amivantamab administered once a month is associated with fewer infusion-related reactions (IRRs) and offers more convenience than the IV formulation, the phase Ib PALOMA study suggest.

Once-monthly subcutaneous amivantamab fares well in advanced solid tumours

02 Jul 2024

News & Updates

Filter by Specialty:

Specialty:

Ocular complications develop in RA, connective tissue disease, vasculitis patients

Ocular complications develop in RA, connective tissue disease, vasculitis patients

Novel agent plus ritonavir show favourable signals for mild-to-moderate COVID-19

Novel agent plus ritonavir show favourable signals for mild-to-moderate COVID-19

ITSH article 2.1

ITSH article 2.1

ITSH article 2.2

ITSH article 2.2

ACOG article 2.6

ACOG article 2.6

ACOG article 2.1

ACOG article 2.1

ACOG article 2.7

ACOG article 2.7

Scenario 3

Scenario 3

Neoadjuvant cycles do not alter perioperative nivolumab benefit in resectable NSCLC

Neoadjuvant cycles do not alter perioperative nivolumab benefit in resectable NSCLC

Once-monthly subcutaneous amivantamab fares well in advanced solid tumours

Once-monthly subcutaneous amivantamab fares well in advanced solid tumours